Target intelligence / Profile preview

CUEDC1 antisense RNA 1 (CUEDC1-AS1)

Target
CUEDC1-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA
01

Overview

CUEDC1 antisense RNA 1 (CUEDC1-AS1), also termed lncCUEDC1, is a nuclear-localized long non-coding RNA transcribed antisense to the CUEDC1 gene. It has been experimentally shown to negatively regulate stem cell-like functions in breast cancer stem cells (BCSCs), mainly by suppression of NANOG expression. Knockdown studies demonstrate that loss of CUEDC1-AS1 increases stemness markers and enhances BCSC phenotypic traits such as mammosphere and colony formation. Its regulatory role can potentially make it a candidate for further exploration as a biomarker or a therapeutic target in cancer stem cell biology. The CUEDC1 gene itself encodes a ubiquitin-binding protein (CUE domain containing 1), which is unrelated to CUEDC1-AS1 except by genomic context. No drugs have been reported to interact with CUEDC1-AS1 directly in published therapeutic pipelines.

Other names
lncCUEDC1Long non-coding RNA CUE domain containing 1
02

Mechanism of action

For knockdown studies, inhibition of CUEDC1-AS1 leads to increased expression of stemness markers such as NANOG, SOX2, and OCT4 in breast cancer cells.

03

Biological functions

Regulation of stemness (inhibits cancer stem cell properties in breast cancer)Potential modulation of gene expression, especially via Nanog inhibition
04

Disease associations

Cancer (suppresses breast cancer stem cell functions)Potential relevance in other stemness-driven pathologies
05

Safety considerations

None specifically identified; therapeutic challenges may include delivery, specificity, and off-target effects—typical for lncRNA-focused therapies.
06

Biomarkers

Lower levels of lncCUEDC1 may be a marker of increased breast cancer stemnessAssociation with stemness markers CD44+/CD24−, NANOG, SOX2, and OCT4

Beyond the preview

Go deeper on CUEDC1 antisense RNA 1 (CUEDC1-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUEDC1 antisense RNA 1 (CUEDC1-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call